Differential effect of NR2A and NR2B subunit selective NMDA receptor antagonists on striato‐pallidal neurons: relationship to motor response in the 6‐hydroxydopamine model of parkinsonism
Open Access
- 4 July 2008
- journal article
- Published by Wiley in Journal of Neurochemistry
- Vol. 106 (2) , 957-968
Abstract
We previously demonstrated that NMDA receptors containing the NR2A or NR2B subunits differentially regulate striatal output pathways. We now investigate whether such a differential control is altered under parkinsonian conditions and whether subunit selective antagonists have different abilities to attenuate parkinsonian‐like motor deficits. Three microdialysis probes were simultaneously implanted in the dopamine‐depleted striatum, globus pallidus and substantia nigra reticulata of 6‐hydroxydopamine hemilesioned rats. The NR2A antagonist NVP‐AAM077 perfused in the striatum reduced pallidal GABA, but not glutamate, levels whereas the NR2B antagonist Ro 25‐6981 was ineffective. Neither antagonist affected striatal or nigral amino acid levels. To investigate whether these neurochemical responses were predictive of different antiparkinsonian activities, antagonists were administered systemically and motor activity evaluated in different motor tasks. Neither antagonist attenuated akinesia/bradykinesia in the bar and drag test. However, NVP‐AAM077 dually modulated rotarod performance (low doses being facilitatory and higher ones inhibitory) while Ro 25‐6981 monotonically improved it. Microdialysis revealed that motor facilitating doses reduced pallidal GABA levels while motor inhibiting doses increased them. We conclude that, under parkinsonian conditions, the striato‐pallidal pathway is driven by striatal NR2A subunits. Motor improvement induced by NVP‐AAM077 and Ro 25‐6981 is accomplished by blockade of striatal NR2A and extrastriatal NR2B subunits, respectively.Keywords
This publication has 53 references indexed in Scilit:
- NR2A and NR2B subunit containing NMDA receptors differentially regulate striatal output pathwaysJournal of Neurochemistry, 2007
- The Nociceptin/Orphanin FQ Receptor Antagonist J-113397 and l-DOPA Additively Attenuate Experimental Parkinsonism through Overinhibition of the Nigrothalamic PathwayJournal of Neuroscience, 2007
- Loss of Synaptic D1 Dopamine/N-Methyl-d-aspartate Glutamate Receptor Complexes in l-DOPA-Induced Dyskinesia in the RatMolecular Pharmacology, 2006
- Prevention of levodopa‐induced dyskinesias by a selective NR1A/2B N‐methyl‐D‐aspartate receptor antagonist in parkinsonian monkeys: Implication of preproenkephalinMovement Disorders, 2005
- Structure–activity analysis of a novel NR2C/NR2D‐preferring NMDA receptor antagonist: 1‐(phenanthrene‐2‐carbonyl) piperazine‐2,3‐dicarboxylic acidBritish Journal of Pharmacology, 2004
- Antiparkinsonian Actions of CP-101,606, an Antagonist of NR2B Subunit-Containing N-Methyl-d-Aspartate ReceptorsExperimental Neurology, 2000
- In Vitro Evidence for Increased Facilitation of Striatal Acetylcholine Release via Pre‐ and Postsynaptic NMDA Receptotors in Hemiparkinsonian RatsJournal of Neurochemistry, 1999
- Antiparkinsonian Actions of Blockade of NR2B-Containing NMDA Receptors in the Reserpine-Treated RatExperimental Neurology, 1999
- Ligand affinities at recombinant receptors depend on subunit compositionEuropean Journal of Pharmacology: Molecular Pharmacology, 1994
- The functional anatomy of basal ganglia disordersTrends in Neurosciences, 1989